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Japan has experienced an epidemic of methamphetamine (MAP) abuse three times: the
first epidemic was from 1951 to 1957, the second epidemic was from 1970 to 1994, and the
third epidemic started in 1995 and continues today. Fortunately, HIV infection is not as
serious a problem in Japan as it is in other countries. The major route of HIV infection in
Japan has been through male homosexual transmission. In cumulative numbers, homo-
sexual transmission accounted for 63% of the 11,146 HIV-positive patients and 40% of 5158
AIDS patients as of December 30, 2011. Intravenous drug use accounted for 0.3% and 0.4%
of these cases, respectively. Drug abuse has changed during the past 20 years in Japan. The
changes are summarized as follows: there has been: (1) a remarkable decrease in solvent
abuse; (2) a stabilization of MAP abuse; (3) a penetration of cannabis abuse; (4) an emer-
gence of evasive drug abuse; and (5) a silent increase in medical drug dependence. This
implies that: (1) there has been a change from a “solvent dominant type” of use to a
“cannabis dominant type,” that is, from a “Japanese type” to a “Western type”; (2) a shift to
drugs which do not have a high potential to cause drug-induced psychosis; and (3) a shift
from conduct that leads to arrest to conduct that does not lead to arrest. Regardless of
whether the drug use is illicit or not, drug dependence is a mental disorder. Japan is urged
to deal with drug abuse and dependence using not only the criminal model, but also the
medical model.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction 2. HIV infection in JapanJapan is now in the 18th year of its third epidemic of meth-
amphetamine (MAP) abuse. However, drug abuse in Japan has
drastically changed in the past 20 years, which wewill explain
in this paper. We begin with a brief discussion of HIV infec-
tion, which is not a serious problem in Japan., Kodaira-shi, Tokyo 187-8
ada).
ministration, Taiwan. PublThe number of HIV-positive people in Japan is very low. Fig. 1
shows the trend of HIV cases by transmission routes. Male
homosexual and heterosexual transmissions have been the
two main routes. In terms of injection drug use, it is not
possible to show such data in Fig. 1 because there have been553, Japan.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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Fig. 1 e Number of HIV-positive cases (per year). Data
source: the national AIDS Surveillance.
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Fig. 3 e Number of arrestees by type of drug involvement.
Data source: “The White Paper on Crime” and “The
General Situation of Administrative Measures against
Narcotics and Stimulants Abuse”.
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drug use each year.
The cumulative number of HIV-positive cases and AIDS
cases among the Japanese were 11,146 and 5,158, respectively,
as of December 30, 2011. Fig. 2 shows the proportion of cu-
mulative HIV-positive patients by transmission routes. Injec-
tion drug use occupies only 0.3%. We think that this situation
is caused by the fact that HIV infection among the general
population is not serious and prevalence of intravenous drug
use is not high in today’s Japan [1].3. Brief history of drug abuse in Japan
The history of drug abuse in Japan started after World War II
and is characterized by three epidemics of MAP abuse (Fig. 3).
The first epidemic was between 1951 and 1957. Under the
pessimistic and pleasure-seeking atmosphere after World
War II, MAP use became a social problem. The second
epidemic was between 1970 and 1994. Around 1970, Japanese
economic growth suddenly fell. This economic deterioration
drove organized gangs to start sellingMAP. The third epidemicHeterosexual,
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Fig. 2 e Cumulative number of HIV-positive cases
(1985e2011) (%). Data source: the National AIDS
Surveillance.started in 1995, after the collapse of the Japanese “Bubble
Economy.”
Japan’s drug abuse issues are easier to understand if dis-
cussed in relation to these three epidemics ofMAP abuse. For a
long time, MAP and organic solvents had been clearly more
problematic than other drugs in Japan [2]. MAP had been
abused mainly by adults, while solvents had been abused
mainly by teenagers [2]. Solvent abuse had been considered a
gateway to MAP abuse in Japan [3].4. Recent drastic changes in the drug abuse
situation in Japan
4.1. From “solvent dominant type” to “cannabis
dominant type”
It has been 18 years since the third epidemic started. One
noticeable change in this period is that cannabis-related ar-
restees outnumbered solvent-related arrestees in 2006 (Fig. 3).
According to the nationwide general population survey on
drug use [2] (Fig. 4), lifetime prevalence of use of any illicit drug
was 2.7% in 2011. The lifetime prevalence of organic solvent
use was the highest, but does not indicate an upward trend.
The lifetime prevalence of cannabis use was the second
highest and indicates an upward trend. The lifetime preva-
lence of MAP use was the third and lowest, and the trend is
stable. Therefore, we consider cannabis has being the drug
with the highest prevalence of use today.
The Nationwide Mental Hospital Survey [2] indicates the
change in the ratio of various “drugs as a main inducing fac-
tor” for users becoming outpatients and inpatients in mental
hospitals (Fig. 5). Organic solvent and MAP use accounted for
40% of such hospitalizations in the second epidemic of MAP
abuse. However, the rate of hospitalizations due to MAP use
increased and those due to organic solvent use drastically
decreased in the third epidemic of MAP abuse. Cannabis
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Fig. 4 e Lifetime prevalence of drug use (aged 15 and over).
Data source: The Nationwide General Population Survey on
Drug Use.
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inducing factor for mental hospitalization. However, the rate
of ever having used cannabis tremendously increased from
10% in 2000 to 40% in 2012 among those admitted to mental
hospitals. Cannabis abuse seems to have spread much more
widely than expected.
These changes imply that drug abuse in Japan changed
from a “Solvent Dominant Type,” which symbolizes a Japa-
nese mode of drug abuse, to a “Cannabis Dominant Type,”
which symbolizes a Western mode of drug abuse.4.2. Emerging evasive drug problem in 2011
Another noticeable change for this period is the evasive drug
problem. This is a serious social issue for today’s Japan.
Evasive drugs are manufactured, sold, and used at large and
are not controlled by law, although they have psychotropic
effects. Evasive drugs first came to the public’s attention in0
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Fig. 5 e The ratio of “drugs as a main inducing factor” for
users becoming outpatients and inpatients in mental
hospitals. Data source: The Nationwide Mental Hospital
Survey.1988, with “magic mushrooms”. Magic mushrooms were
specified as a narcotic material substance in 2002. That was
the first epidemic of evasive drug use in Japan.
After that, several kinds of designer drugs were produced
in order to evade various controls and thwart strengthened
countermeasures. These kinds of drugs had chemical for-
mulas that were partially changed from those of regulated
substances. In those days, we detected three major kinds of
evasive drugs: tryptamines, MDMA analogs, and “2C series.”
Five-methoxy-N,N-diisopropyltryptamine (5MeO-DIPT) espe-
cially became popular in gay communities. This second
epidemic of evasive drug use occurred between 2002 and 2006.
To control these kinds of drugs, we had to collect and
prepare a large amount of scientific data in order for the drug
to be recognized as a “narcotic,” based on the Narcotics Con-
trol Law. However, this takes much time and money. There-
fore, the Ministry of Health, Labor and Welfare revised the
Pharmaceutical Affairs Act and introduced a new concept of
“Designated Substances” in 2006. We can now categorize a
new drug as a “Designated Substance” using comparatively
fewer data. Once the drug is recognized as a Designated
Substance, the manufacture, sale, and purchase of the drug
can be controlled. As a second step, we can then proceed to
prepare the data needed to be recognize a drug as a narcotic
and therefore controlled under the “Narcotics Control Law.”
For several years after introducing the new concept of
Designated Substances, we did not have a social problemwith
“evasive drugs”, and so we thought that the problem of
evasive drugs had disappeared.
However, in 2011, we suddenly had a new serious social
problem with evasive drugs. Many kinds of health accidents
frequently occurred involving these drugs. This is the third
epidemic of evasive drug use. New evasive drugs, named
“evasive herbs”, expanded rapidly in Japan. We can see the
rapid expansion of this drug use by looking at the number of
shops in the Tokyo metropolitan area that sell them. There
were only two shops in 2009, but their number increased to 74
in 2011.
“Evasive herbs” are herbs with evasive drugs, usually
synthetic cannabinoids. Herbs are not the problem. The
evasive drugs that are mixed into the dry herbs are a problem.
We can categorize evasive drugs into three types according to
their forms. The first is “herbs”, the second is “liquids”, and
the third is “powders”. Originally, “herbs” contained de-
pressants such as synthetic cannabinoids. “Liquids” and
“powders” contained mainly stimulants. Synthetic cannabi-
noids are agonists to cannabinoid receptors, CB1. Users take
them, hoping to have similar effects to those of D9-THC.Fig. 6 e Basic structure, (1H-indole -3-yl)(naphthalene-1-yl)
methanone, for “Comprehensive control” of evasive drugs.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 1 ( 2 0 1 3 ) s 3 3es 3 6S36However, the chemical formulas of synthetic cannabinoids
are different from those of D9-THC. Synthetic cannabinoids
cannot be detected using a cannabis detection kit. This im-
plies that users cannot be arrested. The chemicalmechanisms
and effects of most synthetic cannabinoids are not known.
Marijuana and synthetic cannabinoids look alike, but the
substances are different.
Today, the components of evasive drugs are complex. Most
packages of today’s “herbs” contain not only synthetic can-
nabinoids as a depressant but also stimulants. Representative
stimulants are synthetic cathinones.
As for synthetic cannabinoids, there are too many de-
rivatives to recognize them, one by one, as Designated
Substances. The Japanese government established the
“Comprehensive control” system on March 23, 2013. Under
this system, all of the derivatives indicated in Fig. 6 are basi-
cally prohibited. This basic structure comes from the JWH-018
structure. Using this system, we can theoretically control
about 770 synthetic cannabinoids.5. Conclusion
We can summarize the current situation of drug abuse in
Japan as follows: there has been: (1) a remarkable decrease of
solvent abuse; (2) a stabilization of MAP abuse; (3) a penetra-
tion of cannabis abuse; (4) an emergence of evasive drug
abuse; and (5) a silent increase in medical drug dependence.
This implies that there has been: (1) a change from a “solvent
dominant type” to a “cannabis dominant type” of drug use,that is, froma “Japanese type” to a “Western type”; (2) a shift to
drugs which do not have a high potential to cause drug-
induced psychosis; and (3) a shift from conduct that leads to
arrest to conduct that does not lead to arrest.
Regardless of whether a drug is illicit or not, drug depen-
dence is a mental disorder. Japan is urged to deal with drug
abuse and dependence using not only the criminal model, but
also the medical model.Acknowledgments
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